Skin Cancer Non-Melanoma: Low-Risk BCC/SCC
Reviewed by Oncology Team, VICI Healthcare | Last updated: 2026-04
What Non-Melanoma: Low-Risk BCC/SCC Means
BCC: any size without high-risk features. SCC: <4 mm depth, grade 1–2, no perineural invasion. Located on trunk/extremities (lower-risk sites). Well-differentiated histology.
Treatment Approach for Non-Melanoma: Low-Risk BCC/SCC
Mohs micrographic surgery (preferred), wide local excision, curettage and electrodesiccation. Topical 5-fluorouracil or imiquimod for very superficial lesions. Mohs achieves highest cure rates (98%+). Follow-up surveillance at 6 and 12 months, then annually.
Survival Rates and Prognosis
The 5-year survival rate for skin cancer at Non-Melanoma: Low-Risk BCC/SCC is approximately 5-year recurrence-free survival: >95%. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Non-Melanoma: High-Risk BCC/SCC | 5-year recurrence-free survival: 50–80%; metastatic risk 5–20% for aggressive SCC variants | Mohs micrographic surgery or wide local excision with adequate margins (5–10… |
| Melanoma Stage I (T1–2, N0, M0) | 5-year survival: 85–95% (stage IA); 70–80% (stage IB) | Wide local excision (10–20 mm margins depending on thickness and anatomic… |
| Melanoma Stage II (T3–4, N0, M0) | 5-year survival: 60–75% (stage IIA–IIB); 50–60% (stage IIC) | Wide local excision (10–20 mm margins). SLNB strongly recommended. Adjuvant… |
| Melanoma Stage III (T1–4, N1–3, M0) | 5-year survival: 50–70% (stage IIIA); 40–50% (stage IIIB); 25–40% (stage IIIC) | Complete lymph node dissection (CLND) historically standard; trend toward… |
| Melanoma Stage IV (Any T, Any N, M1) | 5-year survival: 20–40% (with modern immunotherapy/targeted therapy); 5–15% (historical, pre-checkpoint inhibitor era) | Systemic therapy: (1) Checkpoint inhibitor monotherapy (pembrolizumab,… |
| Merkel Cell Carcinoma (Stage I–IV) | 5-year survival: 70–80% (stage I); 50% (stage II–III); 25% (stage IV) | Stage I–II: wide local excision (1–2 cm margins) + SLNB + adjuvant radiation…. |
Skin Cancer Treatment in Top Cities
Skin Cancer in Gurgaon
Skin Cancer in Noida
Skin Cancer in Mumbai
Skin Cancer in Bangalore
Skin Cancer in Hyderabad
Skin Cancer in Chennai
Skin Cancer in Kolkata
Diagnosed with Non-Melanoma: Low-Risk BCC/SCC Skin Cancer?
Our specialists can review your reports and create a personalised treatment plan.